Core Viewpoint - The pharmaceutical sector, particularly companies like Eli Lilly and Amgen, has seen significant stock price increases, driven by a shift in investor focus from AI-related stocks to more stable growth stocks in healthcare [2][3][4]. Group 1: Market Trends - The S&P 500 index reached a historical high on October 28, with Eli Lilly's stock rising by 25% and Amgen's by 17% [2]. - AI-related stocks, such as Oracle and Meta, have experienced significant declines, with Oracle down 22% and Meta down 20% [3]. - Investors are reallocating funds from large-cap tech stocks to defensive sectors like healthcare, which are perceived as offering stable growth [3][4]. Group 2: Policy Impact - Concerns over potential drug price reductions under the Trump administration had previously suppressed healthcare stocks, but these fears have begun to ease [4][5]. - A recent agreement between Pfizer and the U.S. government to control drug prices has shifted market perceptions, leading to a more favorable outlook for pharmaceutical companies [4][5]. Group 3: Company Performance - Eli Lilly reported strong earnings for Q3 2025, with its diabetes drug Mounjaro and obesity drug Zepbound exceeding market expectations [5]. - Other companies like Merck and Amgen also reported earnings surpassing market forecasts, contributing to rising stock prices [5]. - Analysts, including Morgan Stanley's Michael Wilson, have a positive outlook on healthcare stocks due to earnings growth, reduced policy uncertainty, and low valuations [5].

Core Viewpoint - The pharmaceutical sector, particularly companies like Eli Lilly and Amgen, has shown significant stock price increases, indicating a shift in investor focus towards stable growth stocks amidst declining AI-related stocks [2][4][5]. Group 1: Market Trends - As of October 28, the S&P 500 index reached a historical high, with Eli Lilly's stock rising by 25% and Amgen's by 17%, reflecting strong performance in the healthcare sector [2][4]. - The decline in AI-related stocks, such as Oracle (down 22%) and Meta (down 20%), has led investors to seek opportunities in defensive stocks like pharmaceuticals [4][5]. - The healthcare sector is viewed as a typical representative of "defensive stocks," expected to provide stable growth [4]. Group 2: Investor Sentiment - Investors are increasingly cautious about large-scale investments in the AI sector, influenced by concerns over potential profit reductions due to intensified competition [5][6]. - Despite the adjustments in AI stocks, investors are not withdrawing from the market, as overall corporate performance remains strong [5][6]. - The healthcare sector, previously overlooked, is now attracting investor interest due to its relatively low valuations [5][6]. Group 3: Policy Impact - A significant change occurred on September 30 when Pfizer reached an agreement with the U.S. government to control drug prices, which is expected to have a limited negative impact on corporate earnings [6]. - The healthcare sector has faced pressure from the Trump administration's drug pricing policies, but recent developments have alleviated some concerns [5][6]. Group 4: Company Performance - Eli Lilly reported strong earnings for Q3 2025, with its diabetes drug Mounjaro and obesity drug Zepbound exceeding market expectations [6]. - Other companies like Merck and Amgen also reported earnings surpassing market forecasts, contributing to further stock price increases [6]. Group 5: Future Outlook - Morgan Stanley's strategist Michael Wilson has a positive outlook on healthcare stocks, citing earnings growth, reduced policy uncertainty, and low valuations as favorable factors [6]. - The healthcare sector's market capitalization is approximately 10%, significantly lower than the nearly 50% share of the tech sector, which may limit its ability to lead the market [7].